ACE-031 1 mg

ACE-031 is a recombinant fusion protein that combines the extracellular domain of the human activin receptor type IIB (ActRIIB) with the Fc fragment of human immunoglobulin G1 (IgG1). In scientific research, it is studied as a model compound and as a soluble ligand decoy receptor in the signaling of the TGF-β superfamily. The compound is offered as a freeze-dried powder (lyophilized powder) and is intended exclusively for laboratory and research purposes.

What is ACE-031?

ACE-031, also referred to by the synonym Ramatercept, belongs to the class of recombinant ActRIIB-Fc fusion proteins. It consists of the ligand-binding, extracellular part of the activin receptor type IIB, which is fused to the Fc domain of human IgG1 via a defined coupling. In research models, the Fc part provides dimerization of the structure and increased molecular stability, making the protein a useful tool for studying receptor-ligand interactions in controlled systems.

The endogenous ActRIIB receptor normally binds multiple signaling factors from the TGF-β superfamily, including myostatin (GDF-8), activin A and B, GDF-11, and several bone morphogenetic proteins (BMPs). As a soluble derivative of that receptor domain, ACE-031 acts as a competitive ligand scavenger in research: it binds these factors in solution before they can reach the receptor on the cell surface. In this way, the subsequent intracellular SMAD signaling pathway is modulated, making ACE-031 a widely used model compound in the study of this signal cascade.

Research areas

• Research into myostatin (GDF-8) and activin signaling and the ligand trap approach in vitro.
• Modeling of the SMAD2/3 signaling pathway after sequestration of ligands from the TGF-β superfamily.
• Study of ActRIIB receptor biology and competitive ligand binding in cell culture models.
• Structural and functional research into Fc fusion proteins, including dimerization, solubility, and stability.
• Comparative study of decoy receptors versus antibody-based approaches to the same signaling pathway.
• Preclinical models regarding the homeostasis of skeletal muscle and bone tissue.

ACE-031 compared with related compounds

ACE-031 acts on the inhibitory axis of the TGF-β superfamily and thereby differs fundamentally from compounds that act on the growth hormone and IGF-1 axes. Whereas ACE-031 sequesters ligands as a soluble receptor, growth hormone secretagogues such as Ipamorelin 10mg and GHRH analogues such as Tesamorelin specifically the release of endogenous growth hormone via their own receptors. Researchers mapping the IGF-1 axis also often place ACE-031 next to IGF-1 LR3 1 mg and the IGF-1-related fragment MGF 2mgThese compounds are used in laboratory research to study various, complementary signaling pathways regarding tissue homeostasis side by side; ACE-031 represents the decoy-receptor approach in this context.

Specifications

Because ACE-031 is a recombinant, glycosylated fusion protein and not a classical small molecule or short peptide, a single CAS number, a molecular formula, and a PubChem CID are deliberately omitted here: for this protein class, those values ​​cannot be determined unambiguously and reliably. The table is therefore limited to the data that can be accurately confirmed.

Shape, handling and storage

ACE-031 is supplied as a freeze-dried powder in a 1 mg vial. As a protein, the compound is more sensitive to mechanical and thermal stress than short synthetic peptides. When reconstituting in a laboratory context, the appropriate solvent is carefully added along the wall of the vial; vigorous shaking and repeated freeze-thaw cycles are avoided to maintain structural integrity. Store the freeze-dried product refrigerated or at -20 °C, protected from light and moisture; after reconstitution, the reconstituted material is kept refrigerated (2–8 °C). All handling takes place exclusively within a research and laboratory setting.

Purity and lab results

ACE-031 is offered with a controlled purity of ≥ 99%. For the associated analytical documentation and a current overview of lab results, please refer to our lab results pageIn this way, the analytical substantiation remains centrally and transparently accessible within the research context.

Frequently Asked Questions

Is ACE-031 a peptide?
No. ACE-031 is a recombinant fusion protein that is significantly larger than the short synthetic peptides. It combines the extracellular domain of ActRIIB with an IgG1-Fc fragment and therefore behaves in research more like a protein than a classical peptide.

What is the difference between ACE-031 and an antibody-based inhibitor?
ACE-031 acts as a soluble decoy receptor that captures ligands in solution via competitive binding. Antibody-based approaches typically target a single specific target protein. This difference in mechanism of action is a widely studied topic in comparative research into the TGF-β signaling pathway.

Which ligands are coupled to ACE-031 in research models?
In the literature, ACE-031 is described as a binding partner for multiple factors from the TGF-β superfamily, including myostatin (GDF-8), activin A and B, GDF-11, and certain BMPs. This broad binding profile makes it an interesting model compound for signaling pathway research.

How do I store ACE-031 in a laboratory setup?
Store the freeze-dried powder refrigerated or at -20 °C, protected from light and moisture. After reconstitution, avoid repeated freeze-thaw cycles and keep the reconstituted material refrigerated at 2–8 °C.

Want to know more? Read our guide: HGH peptides explained: GHRH analogs, GHRPs, and the difference from real growth hormone.

Intended exclusively for laboratory and research purposes. Not for human or animal consumption, or for medical, diagnostic, therapeutic, or cosmetic use. The buyer is 18+ and confirms the research context. Not a medicine.